Capecitabine Market Share

Statistics for the 2023 & 2024 Capecitabine market share, created by Mordor Intelligence™ Industry Reports. Capecitabine share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Capecitabine Industry

The global capecitabine market is moderately competitive and consists of several major players. Few of the prominent players currently dominating the market are applying various strategies like acquiring the products or other companies to consolidate their market positions across the globe and while others are launching generic products. For example, in April 2019, Armas Pharmaceuticals, Inc launched a generic version of Roches's Xeloda, a capecitabine product. Such product launches are expected to propel the market growth. Some of the companies which are currently dominating the market are Cipla Inc., Teva Pharmaceuticals USA Inc, F. Hoffmann-La Roche AG (Genentech, Inc.), Mylan N.V., and Hikma Pharmaceuticals PLC.

Capecitabine Market Leaders

  1. Teva Pharmaceuticals, Inc

  2. F. Hoffmann-La Roche AG (Genentech, Inc.)

  3. Mylan N.V.

  4. Hikma Pharmaceuticals PLC

  5. Cipla Inc.

*Disclaimer: Major Players sorted in no particular order

Teva Pharmaceuticals, Inc., F. Hoffmann-La Roche AG , Mylan N.V., Hikma Pharmaceuticals PLC,  Cipla Inc., Dr. Reddy's Laboratories Ltd., Fresenius SE & Co. KGaA

Capecitabine Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)